AzurRx BioPharma Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AzurRx BioPharma stock.
View analyst ratings for AzurRx BioPharma or view top-rated stocks.

Wall Street analysts have given AzurRx BioPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AzurRx BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AzurRx BioPharma saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,540,000 shares, an increase of 43.9% from the August 15th total of 1,070,000 shares. Based on an average daily volume of 3,910,000 shares, the short-interest ratio is currently 0.4 days.
View AzurRx BioPharma's Short Interest.

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for AzurRx BioPharma.

AzurRx BioPharma's stock was trading at $6.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AZRX shares have decreased by 42.8% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19.

Shares of AzurRx BioPharma reverse split before market open on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of AzurRx BioPharma stock prior to the reverse split would have 10 shares after the split.

4 brokerages have issued 1 year target prices for AzurRx BioPharma's stock. Their forecasts range from $20.00 to $50.00. On average, they expect AzurRx BioPharma's share price to reach $33.33 in the next year. This suggests a possible upside of 847.0% from the stock's current price.
View analysts' price targets for AzurRx BioPharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to AzurRx BioPharma include Lannett (LCI), NeuBase Therapeutics (NBSE), Oasmia Pharmaceutical AB (publ) (OASMY), BioLineRx (BLRX), Lantern Pharma (LTRN), ProMetic Life Sciences (PFSCF), Purple Biotech (PPBT), NuCana (NCNA), Longboard Pharmaceuticals (LBPH), Orgenesis (ORGS), Daré Bioscience (DARE), Eton Pharmaceuticals (ETON), 4D pharma (LBPS), AcelRx Pharmaceuticals (ACRX) and BriaCell Therapeutics (BCTX).
View all of AZRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

(AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

AzurRx BioPharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.14%), Bank of New York Mellon Corp (0.93%), Geode Capital Management LLC (0.46%), Renaissance Technologies LLC (0.19%), Citadel Advisors LLC (0.18%) and Northern Trust Corp (0.13%).
View institutional ownership trends for AzurRx BioPharma.

AZRX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of New York Mellon Corp, Geode Capital Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Goldman Sachs Group Inc., State Street Corp, and Northern Trust Corp.
View insider buying and selling activity for AzurRx BioPharma or or view top insider-buying stocks.

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AZRX stock can currently be purchased for approximately $3.52.

AzurRx BioPharma has a market capitalization of $32.83 million. The company earns $-32,670,000.00 in net income (profit) each year or ($11.50) on an earnings per share basis.

AzurRx BioPharma employs 12 workers across the globe.

The official website for AzurRx BioPharma is www.azurrx.com.

AzurRx BioPharma is headquartered at 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226.

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at (649) 699-7855 or via email at [email protected].com.